Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

15.24 +0.04 (+0.26%)

Delayed Quote Updated: 12:22 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Dyne Therapeutics: Q1 Earnings Insights ↗

May 11, 2023

Via Benzinga

Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 11, 2023

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference

May 03, 2023

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS

May 02, 2023

From Dyne Therapeutics, Inc.

Via GlobeNewswire

What 4 Analyst Ratings Have To Say About Dyne Therapeutics ↗

March 03, 2023

Via Benzinga

Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories" ↗

July 20, 2022

Via Benzinga

Acuity Brands, C3.ai And Other Big Stocks Moving Lower On Tuesday ↗

April 04, 2023

U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

March 23, 2023

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference

March 20, 2023

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Present at Upcoming Investor Conferences

March 07, 2023

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

March 02, 2023

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock ↗

February 27, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 27, 2023 ↗

February 27, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023 ↗

February 15, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 07, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023 ↗

January 26, 2023

Via Benzinga

Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Dyne Therapeutics, Inc.

Via GlobeNewswire

$10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks Insiders Are Buying ↗

December 15, 2022

Although US stocks closed lower on Wednesday following Fed’s rate decision, there were a few notable insider trades.

Via Benzinga

Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session ↗

December 14, 2022

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.

Via Benzinga

REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday ↗

December 14, 2022

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday ↗

November 23, 2022

Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on...

Via Benzinga

Dyne Therapeutics: Q3 Earnings Insights ↗

November 03, 2022

Dyne Therapeutics (NASDAQ:DYN) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:28 AM. Here's what investors need to know about the announcement.

Via Benzinga

Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

November 03, 2022

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Present at Investor Conferences in November

November 02, 2022

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

October 31, 2022

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress

October 11, 2022

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Avidity Biosciences, Kronos Worldwide And Some Other Big Stocks Moving Lower On Tuesday ↗

September 27, 2022

U.S. stocks traded lower, with the Dow Jones dropping around 180 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Dyne Therapeutics: Q2 Earnings Insights ↗

August 04, 2022

Dyne Therapeutics (NASDAQ:DYN) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew ↗

July 12, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗

July 20, 2022

Upgrades

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.